Compare QUALCOMM, Inc. (QCOM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs GeneDx Holdings Corp — how do they compare? QUALCOMM, Inc. trades at $177.44 (market cap $182.87B), while GeneDx Holdings Corp trades at $62.68 (market cap $1.83B). The key difference: QUALCOMM, Inc. is far larger — about 99.9× GeneDx Holdings Corp's market cap, and QUALCOMM, Inc. pays a 2.12% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| QCOM | WGS | |
|---|---|---|
Market Cap | $182.87B | $1.83B |
Sector | Technology | Technology |
52-Week High | $251.10 | $167.51 |
52-Week Low | $124.07 | $34.51 |
Enterprise Value | $188.34B | $1.83B |
Dividend Yield | 2.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $170.32, down 0.85% with bearish technical signals despite recent earnings beats. The stock shows strong fundamentals with 22.31% net margins and 29.27% ROE, though facing margin pressures and smartphone market headwinds. Recent news highlights AI diversification efforts through automotive and data center markets, with CEO Cristiano Amon projecting 'multiple billions' in data center revenue ahead.
Outlook remains mixed with 42.65% analyst buy ratings and $228.22 consensus target suggesting 34% upside, but technical weakness and competitive threats from Nvidia's PC chip entry create near-term uncertainty. Key risks include smartphone demand softness and margin compression, while AI expansion provides long-term growth potential.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
